openPR Logo
Press release

CINV Existing and Pipeline Drugs Market is Expected to Surpass US$1.88 bn by 2020

08-01-2018 02:56 PM CET | Health & Medicine

Press release from: Transparency Market Research

transparency market research

transparency market research

The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances with small companies in order to directly access the consumer base in different geographic locations. However, the global CINV drugs market is highly competitive as a number of generic drugs manufacturers have lined up to enter the market, reports TMR in a new study.

“The global CINV drugs market also consists of a number of Generic drugs manufacturers offering generic versions of first-generation CINV drugs such as 5-HT3RAs Zofran (ondansetron) and Kytril (granisetron). These manufacturers are likely to give stiff competition to key players manufacturing branded drugs,” says the author of the report. Barr Laboratories Inc., Baxter Healthcare, Mylan Pharmaceuticals Inc., Orchid Healthcare, Sandoz (Novartis AG), Sun Pharma, and Teva Pharmaceuticals are some of the key generic manufacturers operating in the market.

Request A Sample Of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776

Rising Demand for CINV Drugs Owing to Increasing Number of Patients Undergoing Chemotherapy

Rising prevalence of cancer has resulted in an increased number of patients undergoing chemotherapy. Various sources indicate that nearly 70% to 80% cancer patients subjected to chemotherapy show nausea and vomiting as major symptoms. Oncologists are thus very likely to prescribe chemotherapy along with CINV drugs to cancer patients, consequently driving the global market. Furthermore, the newer variety of CINV drugs are reported to show better results. They have a higher complete response rate, longer effectiveness, and faster onset. Hence, the approval of such effective drugs can potentially bolster the growth of the CINV drugs market.

The companies are also shifting their focus towards the untapped markets of developing countries. The economic growth, strengthening health insurance policies, and growing occurrence of cancer cases have made developing nations an attractive destination for investments and considerable growth of the global CINV drugs market.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=776

High Development Costs and Stringent Approval Processes Detriment the Growth Rate of CINV Drugs Industry

Despite spending massive amounts-which could go up to US$2 bn-on drug discovery and development, companies often face hurdles in the approval process. This high risk factor is acting against the CINV drugs market’s growth.

Furthermore, the expiration of patents is another challenge that is expected to affect the overall market revenue. Patent expirations will make way for generic versions, which will be sold at prices 80% to 85% lower than branded products, causing massive erosion of profits.

Minimum Side Effects Make Aloxi a Popular Choice Amongst Oncologists and Cancer Patients

5-HT3-receptor antagonists (5-HT3RAs) and Neurokinin1-receptor antagonists (NK1RAs), along with some steroids (less effective or restricted use) are the most prescribed drug classes. Aloxi, a type of 5-HT3RA drug, forms the leading segment by revenue among the major drug type. However, the threat of patent expiration is likely to reduce the revenue generation of the segment to US$ 280.8 mn in 2020, from US$ 447.5 mn in 2015.

“The sales of CINV drugs market will remain healthy in developed regions such as North America and Europe due to the rising incidence of various types of cancer and anticipated product approval during the forthcoming years,” says a TMR analyst. In terms of geography, North America was the leading segment in 2015 and is anticipated to lead till 2020. In Asia Pacific, countries such as India, Japan, Australia, New Zealand, and China offer immense opportunities for the growth of CINV drugs market.

Request For Discount On This Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=776

The information presented in this review is based on a Transparency Market Research report, titled, ‘CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.’

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CINV Existing and Pipeline Drugs Market is Expected to Surpass US$1.88 bn by 2020 here

News-ID: 1157271 • Views: 188

More Releases from Transparency Market Research

Dried Fruits Market Predicted to Witness Surge in The Near Future
Transparency Market Research has published a new report on the global dried fruits market. According to the research report, the dried fruits market is expected to grow at rate of 5.9% CAGR for the period of 2018 to 2026. In 2018, the valuation of the global market was recorded at US$7,255. The competitive landscape of the global dried fruits market is a fragmented one because of the presence of numerous well
Concrete Floor Coatings Market to Reach US$158.0 mn by 2025
The Canada market for concrete floor coatings is characterized by a highly consolidated competitive landscape because of the strongholds of a handful of market players. There is a need to have skilled labor, effective techniques, and a robust industrial base to manufacture concrete floor coatings, and hence, only a countable number of players have risen to reckon in the market. In 2016, 70% of the total market share was held
D-dimer Testing Market Detailed Study of Top Key Players and Their Growth Strate …
The global D-dimer testing market is fairly competitive and the intensity of competition is in all likelihood will intensify over the years. Transparency Market Research (TMR) notes that the constant influx of end users and the large number of acquisitions taking place in the market will raise the ante higher for several prominent diagnostics companies and niche suppliers. Top players operating in the D-dimer testing market include Thermo Fisher Scientific,
Stem Cells Market Trends, Size, Competitive Analysis and Forecast 2017-2025
In the global stem cells market a sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues. In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high

All 5 Releases


More Releases for CINV

CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the
Chemotherapy Induced Nausea and Vomiting CINV Drugs Market Excellent Growth Scop …
A new research study from HTF MI with title Global Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs Market Size, Status and Forecast 2025 provides an in-depth assessment of the Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. The research study provides forecasts for Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs investments till 2022. Access
CINV Existing and Pipeline Drugs Market will Surpass US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
CINV Existing and Pipeline Drugs Market Projected to Reach US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
Chemotherapy-induced Nausea and Vomiting (CINV) Market Grow $2, 659 Million By 2 …
Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects, the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer. For More Info, Get Sample: http://bit.ly/2zVmL28 The global Chemotherapy-induced Nausea and Vomiting market was valued at $1,663 million in 2015 and is estimated to reach $2, 659 million by 2022, registering a CAGR of 7.1%
Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 …
Chemotherapy-induced Nausea and Vomiting (CINV) Market report, published by Allied Market Research, forecasts that the global market is expected to garner $2,659 million by 2022, growing at a CAGR of 7.1% during 2016-2022. Access Full Summary At: https://www.alliedmarketresearch.com/cinv-market Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with